Veradermics Prices Upsized Public Offering and Private Placement to Raise $414.4 Million
MANE has more than doubled off its 52-week low of $32.
Summary
Veradermics announced the pricing of an upsized public offering of common stock and a concurrent private placement of pre-funded warrants, totaling approximately $414.4 million in gross proceeds.
Key Events · Financing and Capital Events · MANE
-
Upsized Public Offering Priced
Veradermics priced an upsized public offering of 3,843,790 shares of common stock at $100.00 per share, expecting gross proceeds of approximately $384.4 million. The offering is priced at a discount to the current stock price of $105.48.
-
Concurrent Private Placement
The company also entered into a private placement agreement to sell 300,000 pre-funded warrants at $99.99999 per warrant, generating approximately $30.0 million in gross proceeds from entities affiliated with Suvretta Capital.
-
Total Capital Raised
The combined public offering and private placement are expected to generate total gross proceeds of approximately $414.4 million, before deducting underwriting discounts and other expenses.
-
Underwriter Option Granted
Veradermics granted underwriters a 30-day option to purchase up to an additional 576,568 shares of common stock at the public offering price.
Analysis · MANE · Life Sciences
Veradermics has finalized the terms of its upsized public offering and a concurrent private placement, securing approximately $414.4 million in gross proceeds. This significant capital raise follows closely on the heels of positive Phase 2/3 clinical trial data for its lead candidate, VDPHL01, announced on April 27, 2026. The funding is crucial for advancing the drug through further development and towards potential commercialization. While the public offering is priced at a modest discount to the current market price, the ability to raise substantial capital, especially near the company's 52-week high, demonstrates investor confidence in its prospects and provides a strong financial runway for its strategic initiatives.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 966 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MANE was trading at $105.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4B. The 52-week trading range was $32.00 to $110.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.